Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 24731496)

1.

[The risks of long-term proton pump inhibitors use].

Jiang X, Zhang Q, Zhang Z, Liu Y.

Zhonghua Yi Xue Za Zhi. 2014 Jan 28;94(4):284-8. Chinese.

PMID:
24731496
2.

Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.

Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, Lamers C, Stockbrügger RW.

Aliment Pharmacol Ther. 1999 Feb;13(2):145-53.

3.

Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial?

Rozgony NR, Fang C, Kuczmarski MF, Bob H.

J Nutr Elder. 2010 Jan;29(1):87-99. doi: 10.1080/01639360903574734.

PMID:
20391044
4.

Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.

Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HL.

Scand J Gastroenterol. 2008 Jan;43(1):20-4.

PMID:
18938772
5.

Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.

Targownik LE, Lix LM, Leung S, Leslie WD.

Gastroenterology. 2010 Mar;138(3):896-904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.

PMID:
19931262
6.

[Risk of long-term treatment with proton pump inhibitors].

Mathieu N.

Rev Prat. 2008 Sep 15;58(13):1451-4. French.

PMID:
18924330
7.

Bone density in proton pump inhibitors users: a prospective study.

Ozdil K, Kahraman R, Sahin A, Calhan T, Gozden EH, Akyuz U, Erer B, Sokmen MH.

Rheumatol Int. 2013 Sep;33(9):2255-60. doi: 10.1007/s00296-013-2709-0. Epub 2013 Mar 2.

PMID:
23455632
8.

Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.

Maggio M, Lauretani F, Ceda GP, De Vita F, Bondi G, Corsonello A, Cattabiani C, Lattanzio F, Ruggiero C, Nouvenne A, Meschi T, Bandinelli S, Ferrucci L.

Bone. 2013 Dec;57(2):437-42. doi: 10.1016/j.bone.2013.09.014. Epub 2013 Sep 26.

PMID:
24076021
9.

The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W; CaMos Research Group.

Am J Gastroenterol. 2012 Sep;107(9):1361-9. doi: 10.1038/ajg.2012.200. Epub 2012 Jul 10. Erratum in: Am J Gastroenterol. 2013 Jan;108(1):157.

PMID:
22777336
10.
11.

[Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin].

Kim BW, Lee BI, Kim HK, Cho YS, Chae HS, Lee HK, Kim HJ, Han SW.

Korean J Gastroenterol. 2009 Feb;53(2):84-9. Korean.

12.

Long-term proton pump inhibitor use in children: a retrospective review of safety.

Tolia V, Boyer K.

Dig Dis Sci. 2008 Feb;53(2):385-93. Epub 2007 Aug 4.

PMID:
17676398
13.

Influence of proton pump inhibitor use in gastrointestinal polyps.

Hsu WH, Wu IC, Kuo CH, Su YC, Lu CY, Kuo FC, Jan CM, Wang WM, Wu DC, Yu FJ.

Kaohsiung J Med Sci. 2010 Feb;26(2):76-83.

PMID:
20123595
14.

Effect of proton-pump inhibitor therapy on serum chromogranin a level.

Pregun I, Herszényi L, Juhász M, Miheller P, Hritz I, Patócs A, Rácz K, Tulassay Z.

Digestion. 2011;84(1):22-8. doi: 10.1159/000321535. Epub 2011 Feb 8.

PMID:
21304238
15.

Uses of proton pump inhibitors and hypomagnesemia.

Gau JT, Yang YX, Chen R, Kao TC.

Pharmacoepidemiol Drug Saf. 2012 May;21(5):553-9. doi: 10.1002/pds.3224. Epub 2012 Feb 15.

PMID:
22337212
16.

Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.

Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K.

Am J Gastroenterol. 2011 Jul;106(7):1209-18; quiz 1219. doi: 10.1038/ajg.2011.113. Epub 2011 Apr 12. Review.

PMID:
21483462
17.

Long-term proton pump inhibitor therapy and risk of hip fracture.

Yang YX, Lewis JD, Epstein S, Metz DC.

JAMA. 2006 Dec 27;296(24):2947-53.

PMID:
17190895
18.

Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.

Ito T, Jensen RT.

Curr Gastroenterol Rep. 2010 Dec;12(6):448-57. doi: 10.1007/s11894-010-0141-0. Review.

19.

Use of proton pump inhibitors and risk of osteoporosis-related fractures.

Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD.

CMAJ. 2008 Aug 12;179(4):319-26. doi: 10.1503/cmaj.071330.

20.

The innovative potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and Lactobacillus delbrueckii Subsp. delbrueckii LDD01 to restore the "gastric barrier effect" in patients chronically treated with PPI: a pilot study.

Del Piano M, Anderloni A, Balzarini M, Ballarè M, Carmagnola S, Montino F, Orsello M, Pagliarulo M, Tari R, Soattini L, Sforza F, Mogna L, Mogna G.

J Clin Gastroenterol. 2012 Oct;46 Suppl:S18-26. doi: 10.1097/MCG.0b013e318267b55d.

PMID:
22955351
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk